"European Patent Office Grants RVX-208 Patent Until 2027"
"Resverlogix Receives $2.5 Million for Non-Core ApoA-I Assets"
TSX Exchange Symbol: RVX
CALGARY, March 17, 2014 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) is pleased to announce today that it has received confirmation that its European patent application covering RVX-208 has been granted. European Patent no. 2118074 is titled "Compounds for the prevention and treatment of cardiovascular diseases." The patent life will extend to February 2027.
"We are delighted to have confirmation of this news," stated Don McCaffrey, President and CEO of Resverlogix. "This additional patent builds upon the growing patent estate for RVX-208, our core asset. With a patent life out to 2027, RVX-208 now has critical protection for the next 13 years in the important European marketplace" McCaffrey added. In addition, Resverlogix has also filed for a fixed dose combination patent, with Rosuvastatin, that if granted will extend the patent life to 2033.
Resverlogix also announced that it entered into a Waiver Agreement with RVX Therapeutics Inc. ("RVX Therapeutics"), a wholly-owned subsidiary of Zenith Epigenetics Corp., whereby Resverlogix agreed to waive its right under a License Agreement dated June 3, 2013 to license any method or pharmaceutical agent within the scope of certain Licensee Patents owned or controlled by RVX Therapeutics that may be determined to come within the ApoA-I Therapeutic Field (as defined in the License Agreement), and RVX Therapeutics agreed not to develop any patents and/or compounds for any indication within the ApoA-I Therapeutic Field for a period of five years. RVX Therapeutics agreed to pay Resverlogix $2.5 million in cash and granted to Resverlogix a right of first refusal for a period of three years thereafter in respect of the license or sale of such patents and/or compounds that are determined to come within the ApoA-I Therapeutic Field. Entering into the Waiver Agreement generated cash for Resverlogix without impacting on its core assets.
In unrelated news, the Company also announced that a March publication in Cell Metabolism titled "High Density Lipoproteins and Cerebrovascular Integrity in Alzheimer's Disease" includes discussion of RVX-208, Resverlogix's small molecule ApoA-I modulator, as a potential therapeutic for Alzheimer's Disease (AD) (Stukas et al., 2014 Cell Metabolism 19: 1-18). Prior exploratory clinical data on the effect of RVX-208 on plasma amyloid beta levels, performed from the Phase Ia and Phase II ASSERT studies, is discussed. As these earlier cardiovascular trials were not specifically designed to study Alzheimer's disease, efforts are being undertaken to advance an exploratory trial in an AD patient population. The Company is planning a Phase II Clinical Trial for the Exploratory Assessment of Alzheimer's Disease following Treatment with RVX-208 in Patients with Alzheimer's and Alzheimer's-like Dementia of Possible Vascular Origin. The trial will target mild to moderate Alzheimer's disease patients.
Additionally, Resverlogix has restructured its clinical CVD program, which will now be formally directed by Dr. Jan Johansson. The Company would like to thank Dr. Allan Gordon for his years of service, and wishes him great success in his future endeavors.
RVX-208 is a first-in-class small molecule that inhibits BET bromodomains. RVX-208 functions by removing atherosclerotic plaque via reverse cholesterol transport (RCT), the natural process through which atherosclerotic plaque is transported out of the arteries and removed from the body by the liver. RVX-208 increases production of Apolipoprotein A-I (ApoA-I), the key building block of functional high-density lipoprotein (HDL) particles and the type required for RCT. These newly produced, functional HDL particles are flat and empty and can efficiently remove plaque and stabilize or reverse atherosclerotic disease. Analysis of recent clinical trials data showed that RVX-208 significantly reduces coronary atherosclerosis and major adverse cardiac events in patients with CVD who have a low level of HDL and elevated CRP, a population with unmet medical need. ApoA-I may also exert beneficial effects in Alzheimer's disease and Diabetes Mellitus. RVX-208 also has anti-inflammatory effects including effects on Interleukin-6 inhibition, vascular cell adhesion-1 and monocyte chemotactic protein-1, factors known to be involved in atherosclerosis and plaque stability.
Resverlogix Corp. (TSX:RVX) is a clinical stage cardiovascular company developing compounds involving ApoA-I production. RVX-208 is a first-in-class small molecule in development for the treatment of diseases such as atherosclerosis, Diabetes Mellitus and Alzheimer's disease. RVX-208 is the first BET bromodomain inhibitor in clinical trials. Resverlogix's common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit www.resverlogix.com. We can be followed on our blog at http://www.resverlogix.com/blog and our IR App found on Apple products iTunes and Android users (Google Play).
This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information relating to research and development activities and the potential role of RVX-208 in the treatment of diseases such as atherosclerosis, Diabetes Mellitus and Alzheimer's disease. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional assumptions and risk factors discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Donald J. McCaffrey
President and CEO
SVP Business & Corporate Development
SOURCE Resverlogix Corp.